Display Settings:

Format

Send to:

Choose Destination
Antimicrob Agents Chemother. 2010 May;54(5):2209-11. doi: 10.1128/AAC.01110-09. Epub 2010 Feb 16.

Lack of a clinically relevant effect of an antacid on the pharmacokinetics of lersivirine.

Author information

  • 1Pfizer Global Research and Development, New London, CT 06320, USA. manoli.vourvahis@pfizer.com

Abstract

Lersivirine (UK-453,061) is a next-generation nonnucleoside reverse transcriptase inhibitor that displays potent antiviral activity. Lersivirine solubility is pH dependent; therefore, the effect of coadministration of antacid on the pharmacokinetics of lersivirine in healthy subjects was investigated. The ratio of adjusted geometric means (750 mg lersivirine plus 20 ml Maalox Max/750 mg lersivirine alone) for the area under the curve from time zero extrapolated to infinite time (AUC(inf)) was 101.86%, showing that coadministration of an antacid had no effect on lersivirine exposure. Coadministration appeared to be safe and relatively well tolerated.

PMID:
20160047
[PubMed - indexed for MEDLINE]
PMCID:
PMC2863683
Free PMC Article

Images from this publication.See all images (1)Free text

FIG. 1.
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for HighWire Icon for PubMed Central
    Loading ...
    Write to the Help Desk